Newsroom
Portola in the News
2009
July 10
Portola Marries Factor Xa Clot Buster Off To Merck
The Pink Sheet
By Emily Hayes
Privately-held Portola Pharmaceuticals has reeled in Merck to develop and commercialize its Phase II Factor Xa inhibitor betrixaban, in the process gaining breathing room to develop other drugs in its pipeline while nurturing hopes for a public offering down-the-line. More
The Pink Sheet
By Emily Hayes
Privately-held Portola Pharmaceuticals has reeled in Merck to develop and commercialize its Phase II Factor Xa inhibitor betrixaban, in the process gaining breathing room to develop other drugs in its pipeline while nurturing hopes for a public offering down-the-line. More
July 10
Portola Inks $470M Deal with Merck for Phase II Anticoagulant
BioWorld Today
By Trista Morrison
Five months after signing a $575 million deal with Novartis AG for the Phase II antiplatelet drug elinogrel, Portola Pharmaceuticals Inc. nailed down a $470 million deal with Merck & Co. Inc. for its other lead compound, the Phase II anticoagulant betrixaban. More
BioWorld Today
By Trista Morrison
Five months after signing a $575 million deal with Novartis AG for the Phase II antiplatelet drug elinogrel, Portola Pharmaceuticals Inc. nailed down a $470 million deal with Merck & Co. Inc. for its other lead compound, the Phase II anticoagulant betrixaban. More